Pfizer Q3 2020 results: China's Pro-Trump results down 21% due to volume purchases

Recently, U.S. pharmaceutical giant Pfizer announced its third-quarter 2020 financial results.
third quarter, global revenue was $12.131 billion, down 4% from a year earlier (at constant exchange rates, the same as between), compared with $35,961 million in the first three quarters, down 8% year-on-year, according to the company's financial results.
's biopharmaceutical division grew 4 percent to $10,215 million in the third quarter, while Pfizer's generic brand and generics division fell 18 percent to $1,916 million.
's national volume procurement policy, which was formally implemented in March 2019 and expanded nationwide in December of that year, has had a continuing impact on the performance of Puqiang.
reporting period, core products such as Lipto (Atovastatin) and Live Hi (ammonia chloride) performed well.
In addition, the new crown outbreak has led to a reduction in the number of selected surgeries in the country, shorter hospital stays and improved infection control measures, resulting in reduced demand for certain anti-infective products, thus affecting Pfizer's Chinese hospital business.
, Pfizer's revenue in China fell 21% year-on-year (specific sales were not reported).
good performance is the strong demand in the Chinese market for Pyr 13 (13-price pneumococcal polysaccharide-binding vaccine).
same time, Pfizer's deal to spin off the merger of Prom and Mylan is expected to close in the fourth quarter of this year.
GBI SOURCE drug database shows that in 2020, Pfizer has launched two products in China, namely, Etogli net tablets (commodity name: Ginoto), chlorobenzene glutamicamine (commodity name: Vidaquan).
addition, there are 65 acceptance numbers involving 33 products of the application for approval, detailed product information can be accessed at the GBI SOURCE drug database for further review.
Schedule: Pfizer's Top 10 Drugs for 2019 (Millions of Dollars)